ClinicalTrials.gg
TerminatedNCT00718640Updated Oct 29, 2013Results posted

An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function

A Phase 2 interventional study of Dexamethasone and Bortezomib in Multiple Myeloma, sponsored by Janssen-Ortho Inc., Canada. Terminated at 5 sites in Canada. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2013-10-29.

Sponsored by Janssen-Ortho Inc., Canada (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Why this study was terminated
Study stopped due to lagging enrolment.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
10
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 271 studies testing bortezomib in Multiple Myeloma — 12 open to participants now, 40 under way, 14 of them phase 3. Bortezomib · Multiple Myeloma.

Enrollment
229th of 267
10 · median 41
Started
2007
with 14 others
Phase 2
137 of 271
6 open now
Registered
93rd of 271
by date

Among the 271 studies testing bortezomib in Multiple Myeloma, this one is the 229th largest by enrollment of the 267 interventional ones that give a count, is one of 15 that started in 2007, is one of 137 in phase 2, and was the 93rd registered.

Multiple Myeloma

3,763 studies on the registry are indexed under Multiple Myeloma; 770 are open to participants now.

Browse Multiple Myeloma studies →

Open to participants now

12 of the 271 studies testing bortezomib in Multiple Myeloma are open now, in 10 countries. Recruiting first, the newest first:

7 more — sign in →

By country, each count listing its studies:

All 12 open studies →

About bortezomib

Bortezomib: first FDA approval 2003 (VELCADE), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 585 Multiple Myeloma studies recruiting now, 430 (74%) set no upper age limit and 106 (18%) stop at 75 or younger; 36 take children under 18; 24 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 271 studies testing bortezomib in Multiple Myeloma, or all of them as a file.
02

Study summary

The purpose of this study is to evaluate the effectiveness and safety of bortezomib in participants previously treated for multiple myeloma (cancer of plasma cells in bone marrow causing numerous tumors and characterized by the presence of abnormal proteins in the blood) with limited kidney function.

Read the detailed description

This is an open label (all people know the identity of the intervention), multi-center (study conducted at multiple sites), non-comparative, single arm study of bortezomib. The study consists of 3 phases: Screening phase (21 days before Day 1 of cycle 1); Treatment phase (consist of 8 cycles each cycle of 21 days or until disease progression or unacceptable toxicity); and a Follow-up phase (for participants with positive treatment response or stable disease at the final visit). Follow-up for disease progression will be done in every 3 months up to 2 years. Participants who will experience disease progression after completing at least 2 cycles of bortezomib treatment or have no change from baseline in stable disease after completing at least 4 cycles or as per Investigator's discretion will receive dexamethasone. Efficacy will be primarily evaluated by percentage of participants with renal compromised Multiple Myeloma by International Myeloma Working Group (IMWG) uniform response criteria. Participants' safety will be monitored throughout the study.

03

Conditions studied

  • Multiple Myeloma

Browse trials for

Keywords

  • Multiple Myeloma
  • Velcade
  • Bortezomib
  • Dexamethasone
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participants diagnosed with symptomatic multiple myeloma based on the International Myeloma Working Group (IMWG) criteria; greater than or equal to 10 percent plasma cells in the bone marrow (or tissue ) detected, monoclonal protein in the serum or urine and the, presence of end-organ injury
  • Participants with defined by at least 1 of the following 5 measurements: a) serum M-protein greater than or equal to 1 gram per deciliter (g/dl), b) Urine M Protein greater than or equal to 200 milligram per 24 hour, c) Serum free light chain (FLC) assay: Involved FLC level greater than 10 mg per dl (mg/dl) provided serum FLC ratio is abnormal, d) Bone marrow plasma cells greater than or equal to 30 percent
  • Participants who received at least 1 for multiple myeloma and, is to or has relapsed after the last therapy
  • Participants with performance status greater than 60 or (ECOG) performance status of 0-2
  • Participants with calculated or measured of less than or equal to 30 mililiter per minute (ml/min). During the screening period, 2 measures of creatinine clearance at least 7 days apart must be obtained, and both must be less than 30 ml/min

Exclusion criteria

Exclusion Criteria:

  • Participants who had received bortezomib in previous clinical trial and best response was progressive disease or experienced one or more serious events
  • Participants who received nitorsoureas within 6 weeks, or 2 consecutive weeks of intense , or immunotherapy or antibody therapy within 4 weeks before enrolment
  • Participants with history of allergic reaction attributable to compounds containing boron or mannitol
  • Participants with peripheral neuropathy of Grade 2 or greater intensity at the time of signing form
  • Pregnant or breast-feeding female participants
Terms in these criteria, in plain language(9)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Line of therapy

A line of therapy is one course of treatment, which may combine several drugs. First-line is the first course given; second-line follows when that stops working or is not tolerated.

“Two prior lines” means two courses that count separately under the study’s rules — not simply two drugs. Ask the study team if you are unsure how yours are counted.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
10 participants (actual)

Study arms

  • Experimental
    Bortezomib and Dexamethasone

    Bortezomib 1.3 milligram (mg) per meter\^2 (m\^2) bolus (a large amount) intravenous (into the vein) injection will be administered once daily on Days 1, 4, 8 and 11 of each 21-day cycle with addition of Dexamethasone 20 mg per day administered orally, once daily on Days 1 and 2, Days 4 and 5, Days 8 and 9 and Days 11 and 12 of each 21-day cycle as per Investigator's discretion for those participants who experience disease progression after treatment completion up to Cycle 2 or have no change from Baseline after completion of at least 4 cycles. The treatment will be given up to 8 cycles (24 weeks).

    Drug: Dexamethasone · Drug: Bortezomib

Interventions

  • Dexamethasone 20 mg per day will be administered orally on Days 1 and 2, Days 4 and 5, Days 8 and 9 and Days 11 and 12 of each 21-days cycle as per Investigator's discretion for those participants who experience disease progression after treatment completion up to Cycle 2 or have no change from Baseline after completion of at least 4 cycles. The treatment will be given up to 8 cycles (24 weeks).

  • Bortezomib 1.3 milligram per meter\^2 (mg/m\^2), bolus intravenous injection will be administered on Days 1, 4, 8 and 11 of each 21-day cycle and up to 8 cycles.

    Also known as: Velcade

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Renal Compromised Multiple Myeloma by International Myeloma Working Group (IMWG) Uniform Response Criteria

    The IMWG uniform response criteria define; Complete response(CR) as negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow(BM). Stringent CR as CR+normal free light chain ratio and absence of clonal cells in BM Very good partial response (PR) as serum and urine M-protein (monoclonal paraprotein) detectable by immunofixation but not on electrophoresis or 90% or \>reduction in serum and urine M-protein level \<100 milligram(mg) per 24 hour(hr).PR as \<=50% reduction of serum and \<= 90% of urine M-protein or up to \<200 mg/24 hr.

    Time frame: Week 24 or Early termination visit (30-45 days after last dose)

Secondary outcomes

  1. Best Response to Treatment

    It was assessed by IMWG criteria. It defines complete response as negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow. Very good partial response as serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or \> reduction in serum and urine M-protein level\<100 mg per 24 hour. Partial Response as \<=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \<=90% or to \<200mg per 24 hr.

    Time frame: Day 1 of Cycle 1, 2, 3, 4, 5, 5, 6, 7, 8 and Final/Early termination visit (30-45 days after last dose)

  2. Time to Progression (TTP) of Disease

    The TTP was defined as the time from the date of starting treatment until the date of first documented evidence of progression of disease or death.

    Time frame: Day 1 (Start of treatment) until the date of first documented evidence of progression of disease or death

  3. Duration of Response

    The duration of Response was defined as the time of first recorded achievement of a particular response level, which was defined according to IMWG uniform response criteria, as either complete response, stringent complete response, very good partial response or partial response included only responding participants, until the participants were assessed to have progressive disease.

    Time frame: Day 1 (Start of treatment) until the date of first documented achievement of response

  4. Eastern Cooperative Oncology Group Performance Status (ECOG PS) Score

    The ECOG PS Score 0 versus 1, wherein 0 signifies fully active, able to carry all pre-disease performance without restriction and 1 signifies restriction in physically strenuous activity but ambulatory (able to walk) and able to carry out work on a light or sedentary nature.

    Time frame: Day 1 of Cycle 1, 3, 5, 7 and Final visit/Early termination visit (30-45 days after last dose)

  5. Karnofsky Performance Status (KPS) Score

    The KPS is used to quantify participant's general well-being and activities of daily life and participants are classified based on their functional impairment. KPS score is 11-level score which ranges between 0 (death) to 100 (no evidence of disease). Higher score means higher ability to perform daily tasks.

    Time frame: Day 1 of Cycle 1, 3, 5, 7 and Final visit (30-45 days after last dose) or early termination visit

  6. Quality of Life Assessment by QLQ C-30

    The quality of life was assessed by the questionnaire QLQ C-30 designed by European Organization for the Research and Treatment of Cancer (EORTC). The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer participants. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the fatigue scale is equal to higher level of symptomatology or problems.

    Time frame: Final Visit/Early termination visit (30-45 days after last dose)

  7. Quality of Life Assessed by Euro Quality of Life (EQ-5D)

    The EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single utility score. It assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression where 1=better health state (no problems), 3=worst health state. Scoring formula was developed by Euro quality of life group which assigns a utility value for each domain in profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

    Time frame: Quality of Life (EQ-5D) Final Visit/Early termination visit (30-45 days after last dose)

  8. Renal Function

    Renal function was analysed by creatinine clearance. Creatinine clearance was calculated by Cockroft-Gault fourmula. Creatinine clearance is equal to 140 minus age multiplied by weight and constant (1 for men and 0.85 for women) divided by creatinine in (micro mole per liter)

    Time frame: Day 1 of Cycle 1, 2, 3, 4, 5, 5, 6, 7, 8 and Final/Early termination visit (30-45 days after last dose)

07

Results

Posted Aug 28, 2013
Limitations and caveats
Participants' recruitment was limited due to pre-defined criteria of renal disease and requirement of repeated evaluation of creatinine clearance. Due to insufficient number of participants the outcome measure data was not analyzed.

Participant flow

Participant flow — Overall Study
MilestoneBortezomib and Dexamethasone
Started10
Completed3
Not completed7
Withdrew: Adverse event4
Withdrew: Death1
Withdrew: Unresolved toxicity after 2 weeks2

Outcome measures

PrimaryPercentage of Participants With Renal Compromised Multiple Myeloma by International Myeloma Working Group (IMWG) Uniform Response Criteria

The IMWG uniform response criteria define; Complete response(CR) as negative immunofixation on serum and urine, disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow(BM). Stringent CR as CR+normal free light chain ratio and absence of clonal cells in BM Very good partial response (PR) as serum and urine M-protein (monoclonal paraprotein) detectable by immunofixation but not on electrophoresis or 90% or \>reduction in serum and urine M-protein level \<100 milligram(mg) per 24 hour(hr).PR as \<=50% reduction of serum and \<= 90% of urine M-protein or up to \<200 mg/24 hr.

Time frame:
Week 24 or Early termination visit (30-45 days after last dose)

No measurements were reported for this outcome.

SecondaryBest Response to Treatment

It was assessed by IMWG criteria. It defines complete response as negative immunofixation on the serum and urine and disappearance of any soft tissue plasmacytomas and \<5% plasma cells in bone marrow. Very good partial response as serum and urine M-protein detectable by immunofixation but not on electrophoresis or 90% or \> reduction in serum and urine M-protein level\<100 mg per 24 hour. Partial Response as \<=50% reduction of serum M-protein and reduction in 24-hour urinary M-protein by \<=90% or to \<200mg per 24 hr.

Time frame:
Day 1 of Cycle 1, 2, 3, 4, 5, 5, 6, 7, 8 and Final/Early termination visit (30-45 days after last dose)

No measurements were reported for this outcome.

SecondaryTime to Progression (TTP) of Disease

The TTP was defined as the time from the date of starting treatment until the date of first documented evidence of progression of disease or death.

Time frame:
Day 1 (Start of treatment) until the date of first documented evidence of progression of disease or death

No measurements were reported for this outcome.

SecondaryDuration of Response

The duration of Response was defined as the time of first recorded achievement of a particular response level, which was defined according to IMWG uniform response criteria, as either complete response, stringent complete response, very good partial response or partial response included only responding participants, until the participants were assessed to have progressive disease.

Time frame:
Day 1 (Start of treatment) until the date of first documented achievement of response

No measurements were reported for this outcome.

SecondaryEastern Cooperative Oncology Group Performance Status (ECOG PS) Score

The ECOG PS Score 0 versus 1, wherein 0 signifies fully active, able to carry all pre-disease performance without restriction and 1 signifies restriction in physically strenuous activity but ambulatory (able to walk) and able to carry out work on a light or sedentary nature.

Time frame:
Day 1 of Cycle 1, 3, 5, 7 and Final visit/Early termination visit (30-45 days after last dose)

No measurements were reported for this outcome.

SecondaryKarnofsky Performance Status (KPS) Score

The KPS is used to quantify participant's general well-being and activities of daily life and participants are classified based on their functional impairment. KPS score is 11-level score which ranges between 0 (death) to 100 (no evidence of disease). Higher score means higher ability to perform daily tasks.

Time frame:
Day 1 of Cycle 1, 3, 5, 7 and Final visit (30-45 days after last dose) or early termination visit

No measurements were reported for this outcome.

SecondaryQuality of Life Assessment by QLQ C-30

The quality of life was assessed by the questionnaire QLQ C-30 designed by European Organization for the Research and Treatment of Cancer (EORTC). The EORTC QLQ-C30 is a 30-item questionnaire to assess the overall quality of life in cancer participants. Most questions used 4-point scale (1 'Not at All' to 4 'Very Much'); 2 questions used 7-point scale (1 'Very Poor' to 7 'Excellent'). Scores are averaged, and transformed to 0-100 scale; higher score for a symptom scale like the fatigue scale is equal to higher level of symptomatology or problems.

Time frame:
Final Visit/Early termination visit (30-45 days after last dose)

No measurements were reported for this outcome.

SecondaryQuality of Life Assessed by Euro Quality of Life (EQ-5D)

The EQ-5D is a participant rated questionnaire to assess health-related quality of life in terms of a single utility score. It assesses level of current health for 5 domains: mobility, self-care, usual activities, pain and discomfort, and anxiety and depression where 1=better health state (no problems), 3=worst health state. Scoring formula was developed by Euro quality of life group which assigns a utility value for each domain in profile. Score is transformed and results in a total score range -0.594 to 1.000; higher score indicates a better health state.

Time frame:
Quality of Life (EQ-5D) Final Visit/Early termination visit (30-45 days after last dose)

No measurements were reported for this outcome.

SecondaryRenal Function

Renal function was analysed by creatinine clearance. Creatinine clearance was calculated by Cockroft-Gault fourmula. Creatinine clearance is equal to 140 minus age multiplied by weight and constant (1 for men and 0.85 for women) divided by creatinine in (micro mole per liter)

Time frame:
Day 1 of Cycle 1, 2, 3, 4, 5, 5, 6, 7, 8 and Final/Early termination visit (30-45 days after last dose)

No measurements were reported for this outcome.

Adverse events

Collected over Day 1 up to 30 days after last dose of study medication. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Bortezomib and Dexamethasone—4/10 (40%)9/10 (90%)
Most frequent serious events
Showing 10 of 11
Most frequent serious events
EventBortezomib and Dexamethasone
PneumoniaInfections and infestations1/10
DiarrhoeaGastrointestinal disorders1/10
Renal impairmentRenal and urinary disorders1/10
HypertensionVascular disorders1/10
Muscle weaknessMusculoskeletal and connective tissue disorders1/10
Depressed level of consciousnessNervous system disorders1/10
AphasiaNervous system disorders1/10
Speech disorderNervous system disorders1/10
Confusion statePsychiatric disorders1/10
Gastrointestinal haemorrhageGastrointestinal disorders1/10
Most frequent other events
Showing 10 of 30
Most frequent other events
EventBortezomib and Dexamethasone
Blood creatinine increasedInvestigations4/10
ThrombocytopeniaBlood and lymphatic system disorders3/10
DyspnoeaRespiratory, thoracic and mediastinal disorders2/10
NeuralgiaNervous system disorders2/10
Muscular weaknessMusculoskeletal and connective tissue disorders2/10
HypokalaemiaMetabolism and nutrition disorders2/10
FatigueGeneral disorders2/10
AnaemiaBlood and lymphatic system disorders2/10
HypotensionVascular disorders1/10
Orthostatic hypotensionVascular disorders1/10

Baseline characteristics

Age, Customized
Age, Customized(participants)Bortezomib and Dexamethasone
< 651
Between 65-691
Between 70-744
>=754
Sex: Female, Male
Sex: Female, Male(Participants)Bortezomib and Dexamethasone
Female6
Male4
08

Study locations

5 sites
  • New Westminster, British Columbia, Canada
  • Vancouver, British Columbia, Canada
  • London, Ontario, Canada
  • Greenfield Park, Quebec, Canada
  • Saint John N/A, Canada
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Oct 2007, a primary completion of Dec 2009 and a completion of Jan 2010. It does not say whether these dates are actual or estimated.

Results were first posted in Aug 2013, 3 years 8 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 17, 2008
First posted
Jul 21, 2008
Start
Oct 2007
Primary completionActual
Dec 2009
CompletionActual
Jan 2010
Results first posted
Aug 28, 2013
Last update
Oct 29, 2013
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 29, 2013, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT00718640
Responsible party
Sponsor
First posted
Jul 21, 2008
Start date
Oct 2007
Primary completion
Dec 2009
Completion
Jan 2010
Results posted
Aug 28, 2013
Last update
Oct 29, 2013

Study contacts

Janssen Inc. Clinical Trial
study director · Janssen Inc.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Sep 2013. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Bortezomib

Start the discussion